Side effects of therapy of hepatitis C and their management. - sprookjes - yvandenbroek - TriplyDB

Side effects of therapy of hepatitis C and their management.

Side effects of therapy of hepatitis C and their management.

http://www.wikidata.org/entity/Q34984142

about

MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications Natural history and clinical response: "it's the virus, stupid, or is it the host?"Chutes and ladders in hepatitis C nucleoside drug development A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection High-Affinity Aptamers to Subtype 3a Hepatitis C Virus Polymerase Display Genotypic Specificity Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture Investigating Toll-Like Receptor Agonists for Potential To Treat Hepatitis C Virus Infection G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease Hepatitis C: a clinical review Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors Interferon therapy in hepatitis C leading to chronic type 1 diabetes Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.Platelet count and sustained virological response in hepatitis C treatment.Type B insulin resistance developing during interferon-alpha therapy.Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection: A Case Report Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis.In vitro and in vivo antioxidative and hepatoprotective activity of aqueous extract of Cortex Dictamni.Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature.Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ

P2860

Q24630291-5F0DE99B-05CD-466A-A94D-322C5895A519 Q24683611-D39D971B-4C6E-47DD-8661-D0546CD9F876 Q26769942-9E62EE0D-8668-47CB-9318-8155FDC7D264 Q26773183-00CA963F-EB21-4766-BA03-384C7B85C582 Q26775018-E0EA1896-984A-4B0C-A479-7B0E9ABA1764 Q26782033-4E4CEE82-513B-4324-96B0-FAE599D4BD34 Q26798477-FBBEC139-7281-4C24-84D6-7FE60DDC1DA2 Q26824094-786F6118-3797-4EBF-9189-7F55DD82F55B Q26998630-F0B18AAD-9486-4628-B10B-3BF313FCE141 Q27023355-266B6C41-4F60-4374-A843-955851EF08B1 Q27477457-ECFC3569-478F-4186-9F5E-371D55A6D7A2 Q27477998-C4C41497-F01D-480C-B951-9DC525B57B05 Q27480270-F1FB2260-A041-4A2C-A2A6-B1353E6BA66A Q27480922-B29DA06E-8FE7-4CD0-8A7C-33917F16E246 Q27490405-A3825D0C-8E71-4B33-B1E5-C3E368124D3F Q27490545-7451715F-050E-4B26-8523-882DA7576B19 Q27490788-B1A59CBA-E64F-4EC7-9A95-333339A22153 Q27490833-C8BBB744-69B5-4C3C-9857-8A59A86BA6FC Q27490955-9F66AD5B-1455-46B4-8ED0-ED3893347E0A Q27671640-40400FB6-2F98-4697-89C0-F04A40DE54C4 Q28080876-CC9BB955-A6A5-4C9E-9C69-07D62D7D47A8 Q28552507-9F6A7C32-0049-4537-908A-F00E32CF624C Q28606732-30104B20-D637-4F4A-AFC8-A9AE33C94F17 Q30405780-BEBCE09C-8FDA-4707-A9D0-7AA88CCDBBE7 Q30426020-07388E37-4798-4512-B865-9C52CEEE59EA Q30655795-A9C8842F-5E95-4BA1-B8F2-E6A15903E959 Q33365990-2881B85A-FC12-4F77-8809-AA53E64B4391 Q33373277-CFA70382-B3C1-48B5-80C4-D50464DDF88C Q33398403-7ABA6CE6-86A1-41F7-B7C4-B45A89C01C0C Q33407719-600B6783-B05C-4408-AC5D-49E976369914 Q33418525-51987145-0CBF-4CEE-A3FF-BD0EB4FA711C Q33425472-EC52EDF0-62F4-4E27-9E9D-4EAC56A995C9 Q33582787-A1DC2D00-75DB-43C6-B5CF-63F5D91E6613 Q33628394-0F49A5AD-5A97-4AA4-B721-62AEF99C8708 Q33639642-15B8895C-1637-4984-89BB-0F31E42F1518 Q33654457-1E990FD4-8B44-4A30-807D-A56DB1D356CC Q33658701-580FEF76-77A8-4FFE-987E-AB755A1F61A1 Q33705645-F0818B1B-66E0-4E4C-BC32-5499C7AE6E8F Q33799276-F7EA14A2-E0A3-4DC4-8E82-E3D62A5CC697 Q33813860-AC959319-D64B-426F-AE9D-BE07849D5000

P2860

Side effects of therapy of hepatitis C and their management.

http://www.wikidata.org/entity/Q34984142

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Side effects of therapy of hepatitis C and their management.

@ast

Side effects of therapy of hepatitis C and their management.

@en

Side effects of therapy of hepatitis C and their management.

@nl

type

label

Side effects of therapy of hepatitis C and their management.

@ast

Side effects of therapy of hepatitis C and their management.

@en

Side effects of therapy of hepatitis C and their management.

@nl

prefLabel

Side effects of therapy of hepatitis C and their management.

@ast

Side effects of therapy of hepatitis C and their management.

@en

Side effects of therapy of hepatitis C and their management.

@nl

P1433

Q34984142-9D9E3714-D60B-49C0-AC66-C2BADD4CA972

P1476

Q34984142-D83C5170-0D9D-4547-850E-090FF87E3B47

P2093

Q34984142-3F8B2B57-2E40-4BB7-BA15-274C8B039C08

P2860

Q34984142-01E694A7-10F4-4155-96EE-6B2BE4EA3F19

Q34984142-039AF0A9-5183-4115-9F8D-888F4A2AD817

Q34984142-0F82AC7A-1665-4EBD-AC83-4D91A522C085

Q34984142-1223E9F0-7D90-4FD0-B23B-1F8F493AF61F

Q34984142-16B9C941-D835-46B8-A006-A81FFD274CFE

Q34984142-1D34036A-8155-4971-A45E-1D24DC7EEBF6

Q34984142-212F443E-2B48-4CA6-8F72-1A3BA5D5A38A

Q34984142-29434F95-5DA1-4E5F-A6E3-EA5A338DD4E1

Q34984142-2E7C142A-0CFD-40DC-B6E4-393977C5FDE5

Q34984142-2EBD9A7C-E4FF-49A9-B63F-6CD7B90985B8

P304

Q34984142-04635E95-2247-4D44-B301-7B64889A4B09

P31

Q34984142-1953537E-F38F-46DD-B456-2B7D6AED7AC6

P356

Q34984142-D0E9FDF0-9D3F-4A52-A8BE-D78EF01E10A8

P407

Q34984142-31CDC629-6F2E-4B39-942F-DACAB97BDCE9

P433

Q34984142-D173553B-9928-4636-888F-CDC568C10FC3

P478

Q34984142-BD1192E5-FF34-4818-857F-773386F23036

P577

Q34984142-E839E41A-3156-4BDA-B8C7-7A4D4ADD6071

P5875

Q34984142-0910498D-65AF-4EFD-9C2C-F686EE228394

P698

Q34984142-D7D8D074-5563-43AA-9E82-D2D5408448C9

P921

Q34984142-a28c7b81-4c2b-3754-42c0-e8e91f3e59a1

P356

JHEP.2002.36810

P1433

P1476

Side effects of therapy of hepatitis C and their management.

@en

P2093

Michael W Fried

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Retinopathy associated with high-dose interferon alfa-2b therapy.

Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, an

Hepatitis C, interferon alfa, and depression.

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.

P304

S237-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2002.36810

http://www.w3.org/2001/XMLSchema#string

P407

P433

5 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2002-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11056256

http://www.w3.org/2001/XMLSchema#string

P698

12407599

http://www.w3.org/2001/XMLSchema#string

P921